ArticleFrontiers in immunology2026
The impact of anti-phosphatidylserine/prothrombin antibodies on pregnancy outcomes in patients with unexplained recurrent implantation failure: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Unexplained recurrent implantation failure (URIF) represents a complex and challenging condition in reproductive medicine, while the role of non-criteria antiphospholipid syndrome antibodies in its pathogenesis remains unclear. As a non-criteria antiphospholipid syndrome antibody, anti-phosphatidylserine/prothrombin antibodies were investigated in this study to explore their effects on oocyte quality and pregnancy outcomes in patients with unexplained recurrent implantation failure. Methods: This was a retrospective cohort study that included 853 IVF/ICSI cycles from patients with URIF at Peking University Third Hospital between April 2021 and April 2023, with patients stratified into positive and negative groups for anti-phosphatidylserine/prothrombin antibodies. Propensity score matching (PSM) was conducted at a 1:3 ratio to adjust for potential confounding factors. The primary outcome was the cumulative live birth rate, and secondary outcomes included the live birth rate per transfer cycle, miscarriage rate, and oocyte quality. Results: After PSM, no significant differences were detected between the aPS/PT-positive and negative groups in terms of the oocyte and embryo parameters. Compared with the aPS/PT-negative group, the positive group presented a lower cumulative live birth rate (20% vs 32.1%, p<0.05) and a higher miscarriage rate (41.4% vs 20.4%, p<0.05). After adjusting for confounding factors via binary logistic regression (for miscarriage) and multivariate Cox models (for cumulative live birth), the results revealed that aPS/PT antibody positivity may be a potential independent risk factor for miscarriage in patients with URIF (OR = 3.753, 95% CI: 1.297-10.854, p<0.05), but its correlation with cumulative live birth rate was not significant (HR = 0.391, 95% CI: 0.391-1.179, p=0.170). Conclusion: Anti-phosphatidylserine/prothrombin antibody (aPS/PT) positivity may be a risk factor for increased miscarriage rates in patients with unexplained recurrent implantation failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.